These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12458126)

  • 21. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez H
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1136-40. PubMed ID: 11897608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of faropenem against 579 strains of anaerobic bacteria.
    Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of anaerobic bacteria to antimicrobial agents.
    Collignon PJ; Munro R; Morris G
    Pathology; 1988 Jan; 20(1):48-52. PubMed ID: 3374973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
    Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
    J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major methodology-dependent discordant susceptibility results for Bacteroides fragilis group isolates but not other anaerobes.
    Aldridge KE; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):135-42. PubMed ID: 7874880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
    Hilliard NJ; Johnson CN; Armstrong SH; Quarles S; Waites KB
    Int J Antimicrob Agents; 2002 Aug; 20(2):136-40. PubMed ID: 12297363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
    Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
    Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
    J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
    Friedland IR; Isaacs R; Mixson LA; Motyl M; Woods GL
    Diagn Microbiol Infect Dis; 2002 May; 43(1):61-4. PubMed ID: 12052630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes.
    Aldridge KE; Morice N; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):227-34. PubMed ID: 7851086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
    Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL
    J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):847-9. PubMed ID: 9087503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ertapenem: a new carbapenem.
    Odenholt I
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic identification and antimicrobial susceptibility of clinically isolated anaerobic bacteria: A prospective multicenter surveillance study in Japan.
    Yunoki T; Matsumura Y; Yamamoto M; Tanaka M; Hamano K; Nakano S; Noguchi T; Nagao M; Ichiyama S;
    Anaerobe; 2017 Dec; 48():215-223. PubMed ID: 28935196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
    Aldridge KE; Morice N; Schiro DD
    Antimicrob Agents Chemother; 1994 Apr; 38(4):889-93. PubMed ID: 8031067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.